GO:0046915 transition metal ion transmembrane transporter activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0046915 defines the molecular function of moving transition metal ions (e.g., Fe, Cu, Zn, Mn, Ni) across biological membranes.
• These transporters are essential for metal homeostasis, and their dysfunction is linked to cancer, diabetes, and neurodegeneration [1,3,4].
• Key gene families include SLC30A1 (ZnT1), SLC6A3 (DAT), ATP7A/B, TMEM165, and HupE, each with distinct metal specificities [2,3,5,7,8].
• Mechanistic studies reveal coupling to proton gradients, ATP hydrolysis, or substrate gradients, often with conformational changes [5,8].
• CRISPR knockout, point mutation, and knock-in models are powerful tools to dissect transporter function in disease contexts [1,3].
• EDITGENE provides end-to-end CRISPR services to accelerate research on transition metal ion transporters.
Description
Transition metal ions such as iron, copper, zinc, manganese, and nickel are indispensable cofactors for numerous enzymes and signaling proteins, yet their accumulation is toxic. Cells therefore rely on dedicated transmembrane transporters to import, export, and compartmentalize these ions. The Gene Ontology (GO) term GO:0046915, transition metal ion transmembrane transporter activity, captures the molecular function of proteins that catalyze the movement of transition metal ions across lipid bilayers. This activity is fundamental to metal homeostasis and is conserved from bacteria to humans. Researchers studying metal-related diseases, including cancer, diabetes, and neurodegenerative disorders, increasingly focus on these transporters as therapeutic targets [1,3,4]. Understanding their mechanisms, regulation, and genetic variants is critical for developing targeted interventions.
transition metal ion transmembrane transporter activity At A Glance
| GO ID | GO:0046915 |
|---|---|
| GO term | transition metal ion transmembrane transporter activity |
| Ontology | molecular_function |
| Synonym | none |
| Major function | Transfer of transition metal ions across membranes |
| Biologically relevant metals | Vanadium, manganese, iron, copper, cobalt, nickel, molybdenum, silver |
| Cellular locations | Plasma membrane, organelle membranes (mitochondria, Golgi, endosomes) |
| Representative genes | SLC30A1, SLC6A3, ATP7A, ATP7B, TMEM165, HupE |
| Disease associations | Cancer, diabetes, neurodegeneration, aldosteronism |
What Is GO:0046915?
GO:0046915, transition metal ion transmembrane transporter activity, is a molecular function that enables the transfer of transition metal ions from one side of a membrane to the other. Transition metals are elements with an incomplete d-subshell in their atomic or ionic form, and biologically relevant examples include vanadium, manganese, iron, copper, cobalt, nickel, molybdenum, and silver. This activity is essential for maintaining metal ion gradients and homeostasis across cellular membranes.
Why Is transition metal ion transmembrane transporter activity Important in Cell Biology?
Transition metal ion transporters are central to cellular physiology because they control the availability of essential metals while preventing toxicity. Dysregulation of these transporters leads to metal imbalance, which is implicated in a wide range of pathologies, including colon tumorigenesis, diabetes mellitus, primary aldosteronism, and neurodegenerative disorders [1,3,4]. Moreover, many transporters are drug targets or influence drug sensitivity, making them attractive for therapeutic development. Studying GO:0046915 therefore provides insights into fundamental cell biology and disease mechanisms.
• Maintains intracellular metal homeostasis and prevents metal-induced oxidative stress.
• Dysfunction is linked to cancer, e.g., PINK1-deficiency causes mitochondrial iron accumulation and colon tumorigenesis.
• Mutations in SLC30A1 (ZnT1) cause aldosterone-producing adenomas and primary aldosteronism.
• Copper transporters are implicated in diabetes mellitus and cardiovascular complications.
• TMEM165 mutations cause congenital disorders of glycosylation, highlighting Golgi manganese transport.
• The dopamine transporter SLC6A3 is a target for psychostimulants and antidepressants.
• Bacterial nickel transporters like HupE inform on metal acquisition and pathogenesis.
• P-type copper ATPases are essential for copper export and are mutated in Menkes and Wilson diseases.
• These transporters are potential targets for antimicrobial and anticancer therapies [7,8].
• CRISPR screens can identify novel transporters and their regulators [1,3].
Mechanism, Genes and Research Methods
Substrate Recognition and Binding
In simple terms: The transporter first grabs the metal ion it needs to move.
Transition metal transporters possess specific metal-binding sites that discriminate among ions based on charge, size, and coordination geometry. For example, the human dopamine transporter SLC6A3 binds its substrate through a central binding pocket that also accommodates inhibitors. In the bacterial HupE Ni2+ transporter, the transmembrane region provides a unique coordination environment that explains its high efficiency for nickel. Similarly, P-type copper ATPases have dedicated copper-binding domains that shuttle the ion to the transmembrane transport site.
Conformational Changes and Ion Translocation
In simple terms: The transporter changes shape to push the ion across the membrane.
After binding, transporters undergo conformational rearrangements that move the ion across the lipid bilayer. The dopamine transporter alternates between outward-facing and inward-facing states, a process that can be locked by inhibitors such as cocaine. P-type ATPases cycle through phosphorylation-dependent conformations to transfer copper against a concentration gradient. The Golgi calcium/manganese-proton antiporter TMEM165 likely uses a similar alternating-access mechanism driven by proton gradients.
Energy Coupling and Regulation
In simple terms: Some transporters use energy to pump ions, while others let ions flow downhill.
Transport can be passive (facilitated diffusion) or active (ATP-driven or ion-gradient-driven). P-type copper ATPases hydrolyze ATP to pump copper ions. TMEM165 functions as a calcium/manganese-proton antiporter, utilizing the proton gradient to drive manganese transport into the Golgi. The activity of these transporters is tightly regulated by cellular metal levels, post-translational modifications, and interacting proteins, ensuring homeostasis.
Physiological Roles and Homeostasis
In simple terms: These transporters keep metal levels balanced in cells and organelles.
Transition metal transporters maintain metal homeostasis in various compartments. Mitochondrial iron accumulation due to PINK1 deficiency promotes colon tumorigenesis, highlighting the importance of mitochondrial iron transport. SLC30A1 (ZnT1) regulates zinc efflux and its mutations lead to aldosterone overproduction. Copper transporters are critical for systemic copper distribution, and their dysfunction contributes to diabetes and neurodegenerative diseases [4,8].
Key Genes Involved in GO:0046915 transition metal ion transmembrane transporter activity
The following genes encode proteins with transition metal ion transmembrane transporter activity (GO:0046915) and are representative of diverse metal specificities and physiological roles.
| Gene | Major Role | Research Relevance |
|---|---|---|
| SLC30A1 | Zinc efflux transporter (ZnT1) | Mutations cause aldosterone-producing adenomas |
| SLC6A3 | Dopamine transporter; also transports trace amines | Target of psychostimulants; involved in dopamine signaling |
| ATP7A | Copper-transporting ATPase | Mutations cause Menkes disease; copper homeostasis |
| ATP7B | Copper-transporting ATPase | Mutations cause Wilson disease; copper export |
| TMEM165 | Golgi Ca2+/Mn2+ antiporter | Mutations cause congenital disorders of glycosylation |
| HupE | Nickel transporter (bacterial) | Nickel uptake; potential antimicrobial target |
| PINK1 | Mitochondrial kinase regulating iron transport | Deficiency leads to mitochondrial iron accumulation and colon cancer |
| SLC11A1 | NRAMP1 metal transporter | Iron/manganese transport; immunity |
| SLC11A2 | DMT1 iron transporter | Intestinal iron absorption |
| SLC39A1 | ZIP1 zinc importer | Zinc uptake; cancer |
| SLC39A4 | ZIP4 zinc importer | Acrodermatitis enteropathica |
| SLC30A10 | Manganese efflux transporter | Manganese homeostasis; neurotoxicity |
| SLC31A1 | Copper importer (CTR1) | Copper uptake; cancer |
| SLC40A1 | Ferroportin iron exporter | Iron export; hemochromatosis |
| SLC25A37 | Mitoferrin-1 mitochondrial iron importer | Mitochondrial iron transport; erythropoiesis |
| SLC25A28 | Mitoferrin-2 mitochondrial iron importer | Mitochondrial iron transport |
| ATP13A2 | Lysosomal polyamine/transition metal transporter | Kufor-Rakeb syndrome; neurodegeneration |
How Is transition metal ion transmembrane transporter activity Regulated?
The activity of transition metal ion transmembrane transporters is regulated at multiple levels. Transcriptional control responds to metal availability via metal-responsive transcription factor 1 (MTF-1) for zinc, or iron regulatory proteins (IRPs) for iron. Post-translational modifications, such as phosphorylation, ubiquitination, and metal-dependent conformational changes, modulate transporter trafficking and activity. For example, PINK1 deficiency alters mitochondrial iron transport, leading to iron accumulation. Copper transporters ATP7A and ATP7B cycle between the trans-Golgi network and the plasma membrane in response to copper levels. Additionally, TMEM165 activity is influenced by Golgi pH and calcium/manganese concentrations.
transition metal ion transmembrane transporter activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| PINK1 | Colon tumorigenesis, mitochondrial iron accumulation | PINK1 knockout colon cancer cell lines |
| SLC30A1 | Aldosterone-producing adenomas, primary aldosteronism | SLC30A1 mutant knock-in adrenal cells |
| ATP7A | Menkes disease, copper deficiency | ATP7A knockout fibroblasts or iPSCs |
| ATP7B | Wilson disease, copper toxicity | ATP7B knockout hepatocytes |
| TMEM165 | Congenital disorders of glycosylation | TMEM165 knockout HeLa or HEK293 cells |
Cancer and Metal Dyshomeostasis
Altered transition metal transport is increasingly recognized in cancer. PINK1-deficiency facilitates mitochondrial iron accumulation and promotes colon tumorigenesis, suggesting that mitochondrial iron transporters contribute to cancer development. Zinc transporter SLC30A1 mutations drive aldosterone-producing adenomas, linking zinc homeostasis to endocrine tumors. Copper transporters are also implicated in cancer progression and angiogenesis, making them potential therapeutic targets.
Metabolic and Endocrine Disorders
Copper homeostasis is disrupted in diabetes mellitus, where altered copper transporter activity contributes to oxidative stress and vascular complications. Mutations in SLC30A1 cause primary aldosteronism, highlighting the role of zinc transport in adrenal steroidogenesis. These findings underscore the importance of metal transporters in metabolic and endocrine diseases.
Neurodegeneration and Neurological Disorders
The dopamine transporter SLC6A3 is a key regulator of dopaminergic signaling and is targeted by psychostimulants; its dysfunction is linked to Parkinson's disease and ADHD. Copper transporter mutations cause Menkes and Wilson diseases, which feature severe neurodegeneration. Manganese transporter defects, such as those in TMEM165 or SLC30A10, lead to neurological impairment.
From transition metal ion transmembrane transporter activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of a transporter affect metal homeostasis? | CRISPR knockout cell lines (e.g., SLC30A1 KO) |
| How do point mutations alter transport activity? | CRISPR point mutation knock-in (e.g., SLC30A1 mutations) |
| What is the subcellular localization of the transporter? | Tagged knock-in (e.g., GFP-ATP7B) |
| Does overexpression of a transporter protect against metal toxicity? | Overexpression cell lines (e.g., SLC30A1 overexpression) |
| Which genes regulate transporter expression? | CRISPR library screening |
| Can we model disease-associated mutations in vivo? | Knock-in mouse models (e.g., ATP7B mutant) |
How to Study the transition metal ion transmembrane transporter activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Gene expression levels | Profiling transporter expression in disease models |
| CRISPR screen | Gene essentiality and fitness | Identifying regulators of metal homeostasis |
| Radioactive transport assay | Metal ion flux | Measuring copper transport by ATP7A/B |
| Fluorescent metal sensors | Intracellular metal concentrations | Real-time zinc imaging in live cells |
| Immunofluorescence | Protein localization | Determining Golgi localization of TMEM165 |
| Proteomics | Protein abundance and modifications | Quantifying SLC30A1 in adrenal tumors |
| Electrophysiology | Ion currents | Studying SLC6A3 transport stoichiometry |
| CRISPR knockout | Gene function | Validating transporter roles in metal homeostasis [1,3] |
Genomic and Transcriptomic Approaches
RNA-seq and single-cell RNA-seq can profile expression of transition metal transporter genes across tissues and conditions. CRISPR screens combined with RNA-seq (e.g., Perturb-seq) can identify transcriptional networks regulated by these transporters. Bioinformatics analysis of metal-responsive elements in promoters helps predict regulatory mechanisms.
Proteomic and Biochemical Assays
Mass spectrometry-based proteomics can quantify transporter protein levels and post-translational modifications. Metal transport activity can be measured using radioactive isotopes (e.g., 64Cu, 65Zn) or fluorescent metal sensors. For example, copper transport by ATP7A/B can be assayed in membrane vesicles.
Imaging and Localization Studies
Fluorescence microscopy of tagged transporters (e.g., GFP-TMEM165) reveals organelle-specific localization and trafficking. Live-cell imaging with metal-sensitive dyes (e.g., FluoZin-3 for zinc) allows real-time monitoring of transport activity. Electron microscopy can provide ultrastructural details of transporter distribution.
Genetic and Pharmacological Perturbations
CRISPR knockout, knockdown (siRNA/shRNA), and overexpression are used to manipulate transporter levels. Pharmacological inhibitors (e.g., cocaine for SLC6A3) help dissect transport mechanisms. Metal chelators and supplements can modulate substrate availability.
How CRISPR Can Be Used to Study GO:0046915 transition metal ion transmembrane transporter activity
Knockout
CRISPR knockout (KO) of transition metal transporter genes enables loss-of-function studies. For example, SLC30A1 KO cells show altered zinc homeostasis and can model primary aldosteronism. PINK1 KO cells exhibit mitochondrial iron accumulation, linking to colon tumorigenesis. KO models are essential for validating gene function and identifying compensatory mechanisms.
Point Mutation
CRISPR point mutation knock-in introduces specific disease-associated mutations. Somatic SLC30A1 mutations found in aldosterone-producing adenomas can be recapitulated in cell lines to study their effects on zinc transport and aldosterone production. Point mutations in ATP7B can model Wilson disease and reveal trafficking defects.
Knock-in
Knock-in of tagged transporters (e.g., GFP or HA) allows visualization and purification. Tagged ATP7A/B knock-in cells facilitate live-cell imaging of copper-induced trafficking. Knock-in of reporter genes (e.g., luciferase) under transporter promoters enables high-throughput screening.
Overexpression
CRISPR activation (CRISPRa) or cDNA overexpression can increase transporter levels. Overexpression of SLC30A1 enhances zinc efflux and protects against zinc toxicity. Overexpression of TMEM165 can rescue glycosylation defects in TMEM165 KO cells. Overexpression models are useful for gain-of-function studies and drug screening.
How EDITGENE Supports transition metal ion transmembrane transporter activity Research
Researchers studying transition metal ion transmembrane transporter activity-related genes often need to determine whether a candidate gene is causally involved in metal homeostasis, disease progression, or drug response. EDITGENE provides comprehensive CRISPR-based services to generate precisely engineered cell models, enabling functional validation and mechanistic studies.
Contact EDITGENE today to design your custom CRISPR model for transition metal ion transmembrane transporter activity research.
Frequently Asked Questions About transition metal ion transmembrane transporter activity
What is GO:0046915?
GO:0046915 is the Gene Ontology term for transition metal ion transmembrane transporter activity, describing proteins that move transition metal ions across membranes.
What genes are involved in transition metal ion transmembrane transporter activity?
Key genes include SLC30A1, SLC6A3, ATP7A, ATP7B, TMEM165, and HupE, among others [2,3,5,7,8].
What diseases are associated with transition metal ion transporters?
They are linked to cancer, diabetes, primary aldosteronism, Menkes disease, Wilson disease, and neurodegeneration [1,3,4,8].
How do transition metal ion transporters work?
They bind specific metal ions and undergo conformational changes to translocate them across membranes, often using ATP or ion gradients [5,8].
What is the role of SLC30A1 in disease?
Mutations in SLC30A1 cause aldosterone-producing adenomas and primary aldosteronism by altering zinc transport.
How can I study transition metal ion transporters?
Use CRISPR knockout, point mutation knock-in, overexpression, and imaging techniques to dissect their function [1,3,5].
What is the function of ATP7A and ATP7B?
They are copper-transporting ATPases that export copper; mutations cause Menkes and Wilson diseases, respectively.
What is TMEM165?
TMEM165 is a Golgi calcium/manganese-proton antiporter; mutations cause congenital disorders of glycosylation.
How does PINK1 relate to iron transport?
PINK1 deficiency leads to mitochondrial iron accumulation and promotes colon tumorigenesis.
What CRISPR services does EDITGENE offer for transporter research?
EDITGENE provides knockout, point mutation, knock-in, overexpression cell models, and CRISPR library screening with bioinformatics support.
Conclusion
GO:0046915, transition metal ion transmembrane transporter activity, is a fundamental molecular function that governs the movement of essential and toxic metals across cellular membranes. Dysregulation of these transporters is implicated in a broad spectrum of diseases, from cancer to neurodegeneration. Advances in CRISPR-based models and screening technologies are accelerating the discovery of new transporters and their roles in health and disease. EDITGENE's comprehensive services empower researchers to dissect these mechanisms with precision.
References
- 1. Arcos M et al.. 2025. PINK1-deficiency facilitates mitochondrial iron accumulation and colon tumorigenesis.. Autophagy 21(4):737-753 PMID: 39512202
- 2. Srivastava DK et al.. 2024. Structure of the human dopamine transporter and mechanisms of inhibition.. Nature 632(8025):672-677 PMID: 39112705
- 3. Rege J et al.. 2023. Somatic SLC30A1 mutations altering zinc transporter ZnT1 cause aldosterone-producing adenomas and primary aldosteronism.. Nat Genet 55(10):1623-1631 PMID: 37709865
- 4. Lowe J et al.. 2017. Dissecting copper homeostasis in diabetes mellitus.. IUBMB Life 69(4):255-262 PMID: 28276155
- 5. Jankauskas SS et al.. 2024. Insights into molecular and cellular functions of the Golgi calcium/manganese-proton antiporter TMEM165.. J Biol Chem 300(8):107567 PMID: 39002685
- 6. Finney LA et al.. 2003. Transition metal speciation in the cell: insights from the chemistry of metal ion receptors.. Science 300(5621):931-6 PMID: 12738850
- 7. Rowińska-Żyrek M. 2018. Metal interactions with the transmembrane region of HupE Ni(2+) transporter explain its efficiency.. J Inorg Biochem 180:33-38 PMID: 29227924
- 8. Inesi G et al.. 2014. Biochemical characterization of P-type copper ATPases.. Biochem J 463(2):167-76 PMID: 25242165
